Official Journal of the European Union

C 176

English edition

Information and Notices

Volume 58

29 May 2015

Contents

EN

IV

(Notices)

NOTICES FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES

EUROPEAN COMMISSION

Summary of European Union decisions on marketing authorisations in respect of medicinal products from 1 February 2015 to 28 February 2015

(Published pursuant to Article 13 or Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council ([1]))

(2015/C 176/01)

([1]) OJ L 136, 30.4.2004, p. 1.

— **Issuing of a marketing authorisation** (Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council): **Accepted**

Date of the decision	Name of the medicinal product	INN (International Non-Proprietary Name)	Holder of the marketing authorisation	Number of the entry in the Community Register	Pharmaceutical form	ATC code (Anatomical Therapeutic Chemical Code)	Date of notification
10.2.2015	Suvaxyn CSF Marker	Live Recombinant E2 gene deleted Bovine Viral Diarrhoea Virus containing Classical Swine Fever E2 (CP7_E2alf)	Zoetis Belgium S.A. Rue Laid Burniat 1, 1348 Louvain-la-Neuve, Belgique	EU/2/14/179	Lyophilisate and solvent for suspension for injection	QI09AD04	12.2.2015

Anyone wishing to consult the public assessment report on the medicinal products in question and the decisions relating thereto is invited to contact:

The European Medicines Agency
30, Churchill Place, Canary Wharf
UK — LONDON E14 5EU

Summary of European Union decisions on marketing authorisations in respect of medicinal products from 1 April 2015 to 30 April 2015

(Published pursuant to Article 13 or Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council ([1]))

(2015/C 176/02)

([1]) OJ L 136, 30.4.2004, p. 1.

— **Issuing of a marketing authorisation** (Article 13 of Regulation (EC) No 726/2004 of the European Parliament and of the Council): **Accepted**

Date of the decision	Name of the medicinal product	INN (International Non-Proprietary Name)	Holder of the marketing authorization	Number of the entry in the Community Register	Pharmaceutical form	ATC code (Anatomical Therapeutic Chemical Code)	Date of notification
13.4.2015	Ristempa	pegfilgrastim	Amgen Europe B.V. Minervum 7061, NL-4817 ZK Breda, Nederland	EU/1/15/996	Solution for injection	L03AA13	15.4.2015
24.4.2015	Arzerra	Ofatumumab	Novartis Europharm Limited Frimley Business Park, Camberley GU16 7SR, United Kingdom	EU/1/10/625	Concentrate for solution for infusion	L01XC10	28.4.2015

— **Modification of a marketing authorisation** (Article 13 of Regulation (EC) No 726/2004 of the European Parliament and of the Council): **Accepted**

Date of the decision	Name of the medicinal product	Holder of the marketing authorisation	Number of the entry in the Community Register	Date of notification
8.4.2015	Adenuric	Menarini International Operations Luxembourg S.A. 1 avenue de la Gare, L-1611 Luxembourg, Grand-Duché de Luxembourg	EU/1/08/447	10.4.2015
8.4.2015	Ammonaps	Swedish Orphan International AB SE-112 76 Stockholm, Sverige	EU/1/99/120	10.4.2015
8.4.2015	Daxas	Takeda GmbH Byk-Gulden-Straße 2, D-78467 Konstanz, Deutschland	EU/1/10/636	10.4.2015
8.4.2015	Dukoral	Valneva Sweden AB SE-105 21 Stockholm, Sverige	EU/1/03/263	13.4.2015
8.4.2015	Invokana	Janssen-Cilag International NV Turnhoutseweg 30, B-2340 Beerse, België	EU/1/13/884	10.4.2015
8.4.2015	ReFacto AF	Pfizer Limited Ramsgate Road, Sandwich, Kent CT13 9NJ, United Kingdom	EU/1/99/103	10.4.2015
8.4.2015	Rivastigmine Sandoz	Sandoz Pharmaceuticals GmbH Raiffeisenstraße 11, D-83607 Holzkirchen, Deutschland	EU/1/09/599	10.4.2015
8.4.2015	Rotarix	GlaxoSmithKline Biologicals S.A. rue de l'Institut 89, 1330 Rixensart, Belgique	EU/1/05/330	10.4.2015
8.4.2015	Sustiva	Bristol-Myers Squibb Pharma EEIG Uxbridge Business Park, Sanderson Road, Uxbridge UB8 1DH, United Kingdom	EU/1/99/110	10.4.2015
9.4.2015	Capecitabine medac	medac Gesellschaft für klinische Spezialpräparate mbH Theaterstr. 6, D-22880 Wedel, Deutschland	EU/1/12/802	13.4.2015
9.4.2015	Clopidogrel Acino	Acino AG Am Windfeld 35, 83714 Miesbach, Deutschland	EU/1/09/532	13.4.2015
9.4.2015	Clopidogrel DURA	Mylan dura GmbH Wittichstraße 6, D-64295 Darmstadt, Deutschland	EU/1/09/560	13.4.2015
9.4.2015	Clopidogrel Mylan	Mylan S.A.S 117 allée des Parcs, F-69800 Saint Priest, France	EU/1/09/559	13.4.2015
9.4.2015	Cubicin	Novartis Europharm Limited Wimblehurst Road, Horsham, West Sussex RH12 5AB, United Kingdom	EU/1/05/328	14.4.2015
9.4.2015	Eucreas	Novartis Europharm Limited Frimley Business Park, Camberley GU16 7SR, United Kingdom	EU/1/07/425	14.4.2015

Date of the decision	Name of the medicinal product	Holder of the marketing authorisation	Number of the entry in the Community Register	Date of notification
9.4.2015	Forsteo	Eli Lilly Nederland B.V. Grootslag 1-5, NL-3991 RA Houten, Nederland	EU/1/03/247	13.4.2015
9.4.2015	Glybera	uniQure biopharma B.V. Meibergdreef 61, NL-1105 BA Amsterdam, Nederland	EU/1/12/791	13.4.2015
9.4.2015	GONAL-f	Merck Serono Europe Limited 56, Marsh Wall, London E14 9TP, United Kingdom	EU/1/95/001	13.4.2015
9.4.2015	Levitra	Bayer Pharma AG D-13342 Berlin, Deutschland	EU/1/03/248	13.4.2015
9.4.2015	M-M-RVAXPRO	Sanofi Pasteur MSD, SNC 162 avenue Jean Jaurès, 69007 Lyon, France	EU/1/06/337	13.4.2015
9.4.2015	Olanzapine Teva	Teva B.V. Swensweg 5, 2031 GA Haarlem, Nederland	EU/1/07/427	13.4.2015
13.4.2015	Axura	Merz Pharmaceuticals GmbH Eckenheimer Landstraße 100 D-60318 Frankfurt am Main, Deutschland	EU/1/02/218	15.4.2015
13.4.2015	Azopt	Alcon Laboratories (UK) Ltd Frimley Business Park, Frimley, Camberley, Surrey, GU16 7SR, United Kingdom	EU/1/00/129	15.4.2015
13.4.2015	Capecitabine Accord	Accord Healthcare Limited Sage House, 319 Pinner Road, North Harrow, Middlesex, HA1 4HF, United Kingdom	EU/1/12/762	15.4.2015
13.4.2015	Clopidogrel ratiopharm GmbH	Archie Samuel s.r.o. Slunná 16, CZ-61700 Brno, Česká republika	EU/1/09/541	15.4.2015
13.4.2015	Ecansya	Krka, d. d., Novo Mesto Šmarješka cesta 6, 8501 Novo mesto, Slovenija	EU/1/12/763	15.4.2015
13.4.2015	Icandra	Novartis Europharm Limited Wimblehurst Road, Horsham, West Sussex RH12 5AB, United Kingdom	EU/1/08/484	16.4.2015
13.4.2015	SonoVue	Bracco International B.V. Strawinskylaan 3051, NL-1077 ZX Amsterdam, Nederland	EU/1/01/177	15.4.2015
13.4.2015	Targretin	Eisai Limited European Knowledge Centre, Mosquito Way, Hatfield, Hertfordshire AL10 9SN, United Kingdom	EU/1/01/178	15.4.2015
13.4.2015	Taxotere	Aventis Pharma S.A. 20 avenue Raymond Aron, F-92165 Antony CEDEX, France	EU/1/95/002	15.4.2015
13.4.2015	Tecfidera	Biogen Idec Limited Innovation House, 70 Norden Road, Maidenhead, Berkshire SL6 4AY, United Kingdom	EU/1/13/837	15.4.2015

Date of the decision	Name of the medicinal product	Holder of the marketing authorisation	Number of the entry in the Community Register	Date of notification
13.4.2015	Zomarist	Novartis Europharm Limited Wimblehurst Road, Horsham, West Sussex RH12 5AB, United Kingdom	EU/1/08/483	16.4.2015
13.4.2015	Zyllt	Krka, d. d., Novo Mesto Šmarješka cesta 6, 8501 Novo mesto, Slovenija	EU/1/09/553	15.4.2015
13.4.2015	Zyprexa	Eli Lilly Nederland B.V. Grootslag 1-5, NL-3991 RA Houten, Nederland	EU/1/96/022	15.4.2015
13.4.2015	Zyprexa Velotab	Eli Lilly Nederland B.V. Grootslag 1-5, NL-3991 RA Houten, Nederland	EU/1/99/125	15.4.2015
15.4.2015	Zevalin	Spectrum Pharmaceuticals B.V. Prins Bernhardplein 200, NL-1097 JB Amsterdam, Nederland	EU/1/03/264	17.4.2015
20.4.2015	Combivir	ViiV Healthcare UK Limited 980 Great West Road, Brentford, Middlesex TW8 9GS, United Kingdom	EU/1/98/058	22.4.2015
20.4.2015	Mekinist	Novartis Europharm Limited Frimley Business Park, Camberley GU16 7SR, United Kingdom	EU/1/14/931	22.4.2015
24.4.2015	Abilify	Otsuka Pharmaceutical Europe Ltd. Gallions, Wexham Springs, Framewood Road, Wexham, SL3 6PJ, United Kingdom	EU/1/04/276	28.4.2015
24.4.2015	ABILIFY MAINTENA	Otsuka Pharmaceutical Europe Ltd. Gallions, Wexham Springs, Framewood Road, Wexham, SL3 6PJ, United Kingdom	EU/1/13/882	28.4.2015
24.4.2015	Atriance	Novartis Europharm Limited Frimley Business Park, Camberley GU16 7SR, United Kingdom	EU/1/07/403	28.4.2015
24.4.2015	Benlysta	Glaxo Group Ltd 980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom	EU/1/11/700	28.4.2015
24.4.2015	Bretaris Genuair	AstraZeneca AB SE-151 85 Södertälje, Sverige	EU/1/12/781	28.4.2015
24.4.2015	Daliresp	Takeda GmbH Byk-Gulden-Straße 2, D-78467 Konstanz, Deutschland	EU/1/11/668	28.4.2015
24.4.2015	Daxas	Takeda GmbH Byk-Gulden-Straße 2, D-78467 Konstanz, Deutschland	EU/1/10/636	28.4.2015
24.4.2015	Deltyba	Otsuka Novel Products GmbH Erika-Mann-Straße 21, D-80636 München, Deutschland	EU/1/13/875	28.4.2015
24.4.2015	Docetaxel Winthrop	Aventis Pharma S.A. 20 avenue Raymond Aron, F-92165 Antony CEDEX, France	EU/1/07/384	28.4.2015

Date of the decision	Name of the medicinal product	Holder of the marketing authorisation	Number of the entry in the Community Register	Date of notification
24.4.2015	Eklira Genuair	AstraZeneca AB SE-151 85 Södertälje, Sverige	EU/1/12/778	28.4.2015
24.4.2015	Fosavance	Merck Sharp & Dohme Limited Hertford Road, Hoddesdon, Hertfordshire EN11 9BU, United Kingdom	EU/1/05/310	28.4.2015
24.4.2015	Galvus	Novartis Europharm Limited Wimblehurst Road, Horsham, West Sussex RH12 5AB, United Kingdom	EU/1/07/414	28.4.2015
24.4.2015	Hycamtin	Novartis Europharm Limited Frimley Business Park, Camberley GU16 7SR, United Kingdom	EU/1/96/027	28.4.2015
24.4.2015	Imatinib Medac	medac Gesellschaft für klinische Spezialpräparate mbH Theaterstr. 6, D-22880 Wedel, Deutschland	EU/1/13/876	28.4.2015
24.4.2015	Jalra	Novartis Europharm Limited Wimblehurst Road, Horsham, West Sussex RH12 5AB, United Kingdom	EU/1/08/485	28.4.2015
24.4.2015	JETREA	ThromboGenics NV Gaston Geenslaan 1, B-3001 Leuven, België	EU/1/13/819	28.4.2015
24.4.2015	Libertek	Takeda GmbH Byk-Gulden-Straße 2, D-78467 Konstanz, Deutschland	EU/1/11/666	28.4.2015
24.4.2015	Luveris	Merck Serono Europe Limited 56, Marsh Wall, London E14 9TP, United Kingdom	EU/1/00/155	28.4.2015
24.4.2015	Onglyza	AstraZeneca AB SE-151 85 Södertälje, Sverige	EU/1/09/545	28.4.2015
24.4.2015	Rapiscan	Rapidscan Pharma Solutions EU Ltd Regent's Place, 338 Euston Road, London NW1 3BT, United Kingdom	EU/1/10/643	28.4.2015
24.4.2015	Tivicay	ViiV Healthcare UK Limited 980 Great West Road, Brentford, Middlesex TW8 9GS, United Kingdom	EU/1/13/892	28.4.2015
24.4.2015	Toujeo	Sanofi-Aventis Deutschland GmbH D-65926 Frankfurt am Main, Deutschland	EU/1/00/133	28.4.2015
24.4.2015	Trobalt	Glaxo Group Ltd 980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom	EU/1/11/681	28.4.2015
24.4.2015	Xiapex	Swedish Orphan Biovitrum AB (publ) SE-112 76 Stockholm, Sverige	EU/1/11/671	28.4.2015
24.4.2015	Xiliarx	Novartis Europharm Limited Wimblehurst Road, Horsham, West Sussex RH12 5AB, United Kingdom	EU/1/08/486	28.4.2015

— **Withdrawal of a marketing authorisation** (Article 13 of Regulation (EC) No 726/2004 of the European Parliament and of the Council)

Date of the decision	Name of the medicinal product	Holder of the marketing authorisation	Number of the entry in the Community Register	Date of notification
13.4.2015	Rienso	Takeda Pharma A/S Dybendal Alle 10, 2630 Taastrup, Danmark	EU/1/12/774	15.4.2015

— **Modification of a marketing authorisation** (Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council): **Accepted**

Date of the decision	Name of the medicinal product	Holder of the marketing authorisation	Number of the entry in the Community Register	Date of notification
9.4.2015	Metacam	Boehringer Ingelheim Vetmedica GmbH D-55216 Ingelheim am Rhein, Deutschland	EU/2/97/004	13.4.2015
13.4.2015	BROADLINE	Merial 29 avenue Tony Garnier, F-69007 Lyon, France	EU/2/13/157	15.4.2015
13.4.2015	Draxxin	Zoetis Belgium S.A. Rue Laid Burniat 1, 1348 Louvain-la-Neuve, Belgique	EU/2/03/041	15.4.2015
13.4.2015	Porcilis Porcoli	Intervet International B.V. Wim de Körverstraat 35, NL-5831 AN Boxmeer, Nederland	EU/2/96/001	15.4.2015
24.4.2015	Porcilis ColiClos	Intervet International B.V. Wim de Körverstraat 35, NL-5831 AN Boxmeer, Nederland	EU/2/12/141	28.4.2015

Anyone wishing to consult the public assessment report on the medicinal products in question and the decisions relating thereto is invited to contact:

The European Medicines Agency
30, Churchill Place, Canary Wharf
UK — LONDON E14 5EU

Summary of European Union decisions on marketing authorisations in respect of medicinal products from 1 April 2015 to 30 April 2015

(Decisions taken pursuant to Article 34 of Directive 2001/83/EC [1] or Article 38 of Directive 2001/82/EC [2])

(2015/C 176/03)

— Issuing, maintenance or modification of a national marketing authorization

Date of the decision	Name(s) of the medicinal product	INN (International Non-Proprietary Name)	Holder(s) of the marketing authorization	Member State concerned	Date of notification
15.4.2015	fentanyl	fentanyl	Not applicable	Not applicable	16.4.2015

[1] OJ L 311, 28.11.2001, p. 67.
[2] OJ L 311, 28.11.2001, p. 1.

ISSN 1977-091X (electronic edition)
ISSN 1725-2423 (paper edition)

Publications Office of the European Union
2985 Luxembourg
LUXEMBOURG

EN